Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Epafipase; PAF-AH; Pafase; Platelet-activating factor acetylhydrolase; Recombinant human platelet-activating-factor acetylhydrolase; rPAF-AH; SUN Y7016

Latest Information Update: 08 Mar 2004

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ICOS Corporation
  • Class Anti-infectives; Anti-inflammatories
  • Mechanism of Action Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute enterocolitis; Adult respiratory distress syndrome; Allergic asthma; Inflammatory bowel diseases; Pancreatitis; Reperfusion injury; Sepsis; Type 1 diabetes mellitus

Most Recent Events

  • 08 Mar 2004 A study has been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 23 Dec 2002 Discontinued - Phase-I for Sepsis in Japan (Injection)
  • 23 Dec 2002 Discontinued - Phase-II for Adult respiratory distress syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top